management

IDSA Updates COVID-19 Treatment Guidelines

The Infectious Diseases Society of America (IDSA) has updated its guidelines for the treatment and management of COVID-19.1

This update focuses on the use of lopinavir/ritonavir following the results of 3 randomized controlled trials. The new recommendations state that lopinavir/ritonavir should not be used for post-exposure prophylaxis in individuals exposed to COVID-19 or among ambulatory patients with mild to moderate disease.

Prior to this update, the panel recommended against the use of lopinavir/ritonavir in individuals hospitalized with COVID-19. All recommendations concerning lopinavir/ritonavir are strong recommendations with moderate certainty of evidence.

The panel also recently recommended the use of remdesivir within 7 days of symptom onset in individuals with mild to moderate COVID-19 who are at high risk of progression to severe disease (conditional recommendation, low certainty of evidence).2 This recommendation includes both ambulatory and hospitalized patients.

The use of FDA-qualified high-titer COVID-19 convalescent plasma within 8 days of symptom onset has also been recently recommended for ambulatory patients with mild to moderate COVID-19 who are at high risk of progression to severe disease (conditional recommendation, low certainty of evidence).3

 

—Leigh Precopio

 

References:

  1. Infectious Diseases Society of America. IDSA guideline on the treatment and management of COVID-19: lopinavir/ritonavir. IDSA. Published February 22, 2022. Accessed February 25, 2022. https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt---lopinavir-ritonavir-2022-02-16.pdf
  2. Infectious Diseases Society of America. IDSA guideline on the treatment and management of COVID-19: remdesivir. IDSA. Published February 7, 2022. Accessed February 25, 2022. https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt---remdesivir-2022-02-07.pdf
  3. Infectious Diseases Society of America. IDSA guideline on the treatment and management of COVID-19: convalescent plasma. IDSA. Published February 3, 2022. Accessed February 25, 2022. https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt---convalescent-plasma-2022-02-03.pdfv